Breaking News Instant updates and real-time market news.

KO

Coca-Cola

$54.24

0.37 (0.69%)

, BIIB

Biogen

$284.21

2.25 (0.80%)

10:09
10/23/19
10/23
10:09
10/23/19
10:09

Fly Intel: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Coca-Cola (KO) upgraded to Buy from Neutral at UBS with analyst Sean King saying the company is "effectively navigating" aggressive U.S. price increases, a transformational deal for Costa, and demonstrating strong innovation capabilities while reinvigorating growth in high-margin sparkling. 2. Biogen (BIIB) upgraded to Outperform from Market Perform at SVB Leerink and to Buy from Neutral at Guggenheim. 3. Snap (SNAP) upgraded to Overweight from Neutral at JPMorgan and to Hold from Underperform at Needham. 4. Travelers (TRV) upgraded to Hold from Sell at Deutsche Bank with analyst Joshua Shanker saying while management warned investors six weeks ago to expect headwinds from a challenging environment from tort severity, Travelers' Q3 results were still materially worse than expected. 5. PPL Corp. (PPL) upgraded to Neutral from Underperform at Macquarie with analyst Angie Storozynski saying an M&A deal is increasingly likely as it would solve the company's balance sheet and dividend problems. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

KO

Coca-Cola

$54.24

0.37 (0.69%)

BIIB

Biogen

$284.21

2.25 (0.80%)

SNAP

Snap

$14.13

0.13 (0.93%)

TRV

Travelers

$131.52

1.3 (1.00%)

PPL

PPL Corp.

$32.97

0.23 (0.70%)

  • 05

    Nov

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

  • 21

    Nov

KO Coca-Cola
$54.24

0.37 (0.69%)

10/23/19
UBSW
10/23/19
UPGRADE
Target $63
UBSW
Buy
Coca-Cola upgraded to Buy from Neutral at UBS
UBS analyst Sean King upgraded Coca-Cola to Buy from Neutral with a price target of $63, up from $55. The stock closed Tuesday down 38c to $53.85. The company is "effectively navigating" aggressive U.S. price increases, a transformational deal for Costa, and demonstrating strong innovation capabilities while reinvigorating growth in high-margin sparkling, King tells investors in a research note. These "comfortably position" Coca-Cola to deliver on growth targets and improve free cash flow through fiscal 2022, adds the analyst. He believes the company's earnings, range bound since 2011, have reached a "sustainable fundamental inflection" that will drive a multiple re-rating.
10/02/19
BMOC
10/02/19
NO CHANGE
Target $34
BMOC
Outperform
BMO Capital more optimistic about Keurig Dr Pepper generating merger synergies
BMO Capital analyst Amit Sharma is keeping his Outperform rating and $34 price target on Keurig Dr Pepper (KDP), citing its expected "sector leading" mid-teen earnings growth through 2021 along with his "greater confidence" in post-synergies earnings growth potential in high single digits. The analyst notes that investors are focusing on the company's coffee business while overlooking the "ingrained structural advantages" of its much-larger RTD beverage business, with consensus estimates modeling a "smaller" improvement than the expected North America sales trends at Coca-Cola (KO) and PepsiCo (PEP).
10/02/19
GUGG
10/02/19
DOWNGRADE
Target $60
GUGG
Neutral
Guggenheim downgrades Monster Beverage to Neutral as Coke Energy comes to U.S.
As previously reported, Guggenheim analyst Laurent Grandet downgraded Monster Beverage (MNST) to Neutral from Buy given his view that the stock will be range-bound until the market can better gauge the impact of the upcoming U.S. launch of Coca-Cola (KO) Energy, which is planned for January. In Europe, where Coke has already launched Energy, there are signs of softness for Monster, though there is also broader category slowdown there and the long-term impact is still unknown, added Grandet. He lowered his EPS estimates for Monster for FY19-FY21 and cut his price target on the shares to $60 from $74.
10/23/19
MSCO
10/23/19
NO CHANGE
Target $125
MSCO
Overweight
Procter & Gamble results could bode well for Walmart, says Morgan Stanley
Morgan Stanley analyst Simeon Gutman noted that three of the four companies with the greatest weight in the Consumer Staples Sector SPDR (XLP) - PepsiCo (PEP), Coca-Cola (KO) and now Procter & Gamble (PG) - have reported solid Q3 results. He thinks the group's momentum could have a positive read-through to Walmart (WMT), which will report its fiscal Q3 results on November 14. Gutman added that the correlation between Walmart's total comps and P&G volume growth on a trailing five year basis has improved in the past couple of quarters and both companies' revenue trajectories have trended in a similar direction since "around 2015." Gutman keeps an Overweight rating on Walmart shares with a $125 price target.
BIIB Biogen
$284.21

2.25 (0.80%)

10/23/19
BOFA
10/23/19
NO CHANGE
Target $235
BOFA
Underperform
BofA reiterates Underperform rating on Biogen, still sees commercial headwinds
BofA Merrill Lynch analyst Geoff Meacham continues to be cautious on Biogen and reiterates his Underperform rating on the stock given the commercial headwinds he still sees facing the company, though he raised his price target to $235 from $200 given the Alzheimer's disease pipeline optionality following the "stunner" yesterday that the company sees a path to file a BLA with the FDA for aducanumab. Despite the unmet medical need in Alzheimer's, he does not see the FDA as likely to relax approval criteria for "a mixed approval package" and thinks the most logical path is a two-year pivotal study of high-dose aducanumab in a pre, not post, approval setting, Meacham tells investors.
10/23/19
LEER
10/23/19
UPGRADE
Target $350
LEER
Outperform
Biogen upgraded to Outperform at SVB Leerink
As previously reported, SVB Leerink analyst Geoffrey Porges upgraded Biogen to Outperform from Market Perform with a price target of $350, up from $256. The analyst is ambivalent about the prospects for the company's most important product, which is once again aducanumab, but even with relatively conservative assumptions, and a 50% probability of approval, his fair value estimate for the stock easily reaches $350.
10/23/19
BMOC
10/23/19
NO CHANGE
Target $297
BMOC
Market Perform
Biogen price target raised to $297 from $250 at BMO Capital
BMO Capital analyst George Farmer raised his price target on Biogen to $297 after its new results from Phase 3 trials supported the potential of aducanumab in the treatment of early Alzheimer's disease. The analyst notes that his new price target reflects the update of his model to include a-mab sales and royalty estimates, but he keeps his Market Perform rating on the stock pending presentation of a-mab Phase 3 results atCTAD in December.
10/23/19
MSCO
10/23/19
NO CHANGE
Target $262
MSCO
Underweight
Morgan Stanley withholds aducanumab judgement for now, stays Underweight Biogen
Morgan Stanley analyst Matthew Harrison estimates Biogen trading around $300 per share seems to imply 50% odds of success being attributed for aducanumab in Alzheimer's disease, but he is withholding judgement on aducanumab for now as "yesterday's disclosure breaks all the traditional rules related to clinical development and regulatory filings." Though he raised his price target on Biogen shares to $262 from $212, Harrison keeps an Underweight rating on the stock, citing three major reasons: the need greater data disclosure on aducanumab; his belief that there is more downside than upside risk; and the underlying fundamentals that he sees continuing to be under pressure.
SNAP Snap
$14.13

0.13 (0.93%)

10/23/19
NEED
10/23/19
UPGRADE
NEED
Hold
Snap upgraded to Hold from Underperform at Needham
Needham analyst Laura Martin upgraded Snap to Hold after its Q3 earnings beat, saying that based on its Q4 EBITDA guidance, she now expects the company to reach breakeven free cash flows in Q1 of 2020. The analyst notes that the company has "met its promise" to reduce costs and drive margin expansion, while its $1.1B convertible debt issuance in August has added to its balance sheet strength. Martin further cites Snap's improved revenue trajectory with a "growing number of 'always on' advertisers".
10/23/19
JPMS
10/23/19
UPGRADE
Target $20
JPMS
Overweight
JPMorgan upgrades 'increasingly compelling' Snap to Overweight from Neutral
JPMorgan analyst Doug Anmuth upgraded Snap to Overweight from Neutral with a price target of $20, up from $17. The stock in premarket trading is up 2% to $14.33. Following a 20% pullback from recent highs and last night's Q3 results that "showed more encouraging trends," Snap shares are "increasingly compelling," Anmuth tells investors in a research note. The analyst believes Snap's platform and business have both "improved dramatically over the past several quarters." Daily active users have now increased for three straight quarters, accelerating to 13% growth in Q3, while daily time spent continues to run at 30-plus minutes per user, Anmuth points out. Further, the analyst thinks Snap is at an "inflection point" with positive EBITDA for the first time in Q4.
10/23/19
NEED
10/23/19
UPGRADE
NEED
Hold
Snap upgraded to Hold from Underperform at Needham
10/23/19
RSBL
10/23/19
NO CHANGE
Target $21
RSBL
Buy
Snap shares should be bought on post-earnings weakness, says Rosenblatt
Rosenblatt analyst Mark Zgutowicz reiterates his Buy rating and $21 price target on shares of Snap following the company's Q3 report, stating that he would be a buyer on any weakness in the shares today. Snap's outlook remains "stellar" in terms of both product and demand and he suspects the company's Q4 guidance will prove conservative, Zgutowicz tells investors. Beyond the upcoming holiday quarter, management remains focused on executing and he predicts "a long consistent trajectory ahead," the analyst added.
TRV Travelers
$131.52

1.3 (1.00%)

10/23/19
DBAB
10/23/19
UPGRADE
Target $140
DBAB
Hold
Travelers upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Joshua Shanker upgraded Travelers last night to Hold from Sell with a price target of $140, up from $136. While management warned investors six weeks ago to expect headwinds from a challenging environment from tort severity, Travelers' Q3 results were still materially worse than expected, Shanker tells investors in a research note. The company's deteriorating underwriting margins suggest that it is acknowledging losses in its financials earlier than its peers and that its loss picks for recent accident-years are likely more conservative than peers, contends the analyst. As such, he believes Travelers Business Insurance's underwriting margins may be nearing a trough.
10/23/19
MKMP
10/23/19
NO CHANGE
Target $130
MKMP
Neutral
Travelers price target lowered to $130 from $140 at MKM Partners
MKM Partners analyst Harry Fong lowered his price target on Travelers to $130 and kept his Neutral rating after its Q3 earnings miss driven by the "worsening tort environment". The analyst contends however that earnings will improve as rate increases roll through the company's book of business, noting that as many industry analysts know, the pricing power in insurance only surfaces after the recognition of losses. Fong adds that the 4.3% renewal rate change in teh quarter and the the 7.4% renewal premium change in business insurance were the highest since 2014.
10/23/19
MSCO
10/23/19
NO CHANGE
Target $125
MSCO
Underweight
Travelers still faces reserve risk, says Morgan Stanley
Morgan Stanley analyst Michael Phillips said Travelers' Q3 reserve charge "marked a material change from years of releases" and although year-to-date General Liability and Commercial Auto Liability reserve charges of about $370M improves the reserve position, adjusted reserves are still below the midpoint of his range and he believes the risk of continued charges remains. Following the company's Q3 report, Phillips reduced his 2020 EPS estimate on lower reserve development and expected net interest income and he cut his price target on Travelers shares to $125 from $136. He keeps an Underweight rating on the stock.
10/22/19
DBAB
10/22/19
UPGRADE
Target $140
DBAB
Hold
Travelers upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Joshua Shanker upgraded Travelers to Hold from Sell with a price target of $140.
PPL PPL Corp.
$32.97

0.23 (0.70%)

08/07/19
BOFA
08/07/19
UPGRADE
BOFA
Neutral
PPL Corp. upgraded to Neutral from Underperform at BofA/Merrill
10/23/19
MACQ
10/23/19
UPGRADE
Target $32.5
MACQ
Neutral
PPL Corp. upgraded to Neutral from Underperform at Macquarie
Macquarie analyst Angie Storozynski upgraded PPL Corp. to Neutral from Underperform with a price target of $32.50, up from $27 saying an M&A deal is increasingly likely as it would solve the company's balance sheet and dividend problems. The analyst said speculation of a AGR merger makes sense given the combination of their US businesses/balance sheets makes sense and cost benefits. AGR would contribute a strong balance sheet, grow its size/trading liquidity, and avoid another earnings CAGR reset, which would be inevitable on a standalone basis. PPL would contribute decent regulated utilities in good jurisdictions, strong management track record, while avoiding a dividend cut or equity raise, Storozynski wrote in a note to investors.
08/07/19
BOFA
08/07/19
UPGRADE
Target $30
BOFA
Neutral
PPL Corp. upgraded to Neutral from Underperform at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith upgraded PPL Corp to Neutral with a $30 price target after its Q2 earnings beat and backed Ofgem expectations. The analyst notes however that the stock has underperformed its peers by nearly 15% year-to-date because of its lower premium to Regulatory Asset Value for its UK business and sees "substantial negativity" weighing further on shares based on the impact of GBP F/X rates and UK's RIIO-ED2 rate review process. Dumoulin-Smith also sees a "more balanced risk-reward" after the management backed its dividend payout expectations.
08/07/19
08/07/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. WW (WW) upgraded two notches to Buy from Underperform at BofA/Merrill and upgraded to Buy from Neutral at B. Riley FBR. 2. Boston Beer (SAM) upgraded to Outperform from Neutral at Macquarie with analyst Caroline Levy citing IRI data that showed sales were up 35% in the 4 weeks ended July 28, which she said confirmed the company's strong sales trends and continued momentum in its portfolio. 3. PPL Corp. (PPL) upgraded to Neutral from Underperform at BofA/Merrill with analyst Julien Dumoulin-Smith citing its Q2 earnings beat and backed expectations. 4. Dunkin' Brands (DNKN) upgraded to Buy from Hold at Argus with analyst John Staszak saying he sees the company growing its comps and accelerating its location openings with the positive view on the upgrades in store experience that includes drive-thru lines for mobile orders, brighter interior designs, espresso machines, digital order boards, and a coffee tap system. 5. Electronic Arts (EA) upgraded to Overweight from Neutral at Atlantic Equities. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.